Mesoblast Ltd is primarily active in the biotechnology and regenerative medicine industries.

Some of the main competitors of Mesoblast Ltd in the market are Novartis AG, Johnson & Johnson, Pfizer Inc., and Athersys Inc.

Mesoblast Ltd is a renowned biopharmaceutical company specializing in the development of innovative cellular medicines. Founded in 2004, Mesoblast has excelled in the field of regenerative medicine, aiming to provide effective treatments for challenging inflammatory ailments. With a focus on harnessing the unique regenerative properties of cells, Mesoblast has successfully developed a diverse pipeline of potential therapies. The company has made significant strides in areas such as cardiovascular conditions, orthopedic disorders, and immune-mediated diseases. Mesoblast's dedication to innovation and scientific excellence has positioned it as a global leader in the field of cellular medicines.

Mesoblast Ltd, a leading biopharmaceutical company, has achieved several significant milestones. Notably, the company successfully completed a Phase 3 pivotal trial for its flagship product, remestemcel-L, in the treatment of graft-versus-host disease (GVHD). Mesoblast also received fast track designation from the U.S. FDA for this potential groundbreaking therapy. Additionally, the company forged strategic partnerships with major pharmaceutical companies, including JCR Pharmaceuticals and Grünenthal, to expand its product pipeline and accelerate commercialization efforts. Mesoblast's groundbreaking research and development efforts, along with its partnerships and successful clinical trials, demonstrate its commitment to revolutionizing the treatment of various diseases and solidify its position as an innovative leader in the healthcare industry.

Mesoblast Ltd is primarily present in multiple countries and regions worldwide. The company's global presence extends to various key markets, including the United States, Japan, Australia, and Europe. With a robust international footprint, Mesoblast Ltd has established itself as a leading biopharmaceutical company, dedicated to innovative cellular medicines.

Mesoblast Ltd represents values of innovation, integrity, and collaboration in the field of regenerative medicine. The company aims to develop and commercialize cell-based therapies that have the potential to improve patients' lives. With a focus on advanced manufacturing and rigorous clinical trials, Mesoblast is committed to delivering safe and effective treatments for a variety of conditions, including cardiovascular diseases, orthopedic disorders, and immune-mediated inflammatory diseases. By collaborating with leading research institutions and pharmaceutical partners, Mesoblast strives to be at the forefront of scientific advancements and bring innovative therapies to the market.

Analysts currently set an average price target of 2,69 USD for the Mesoblast stock (median: 2,51 USD), implying +77,7 % versus the latest price. The consensus is based on 10 analyst ratings.

Mesoblast Analyytikkojen kursstavoitteet 2026

10 analysts currently rate the Mesoblast stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Mesoblast to generate revenue of 124,91 M USD and earnings per share of −0,04 USD.

Mesoblast Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Mesoblast share trades at 1,31 EUR (1,51 USD).

The Mesoblast share (MSB.AX) is listed on 6 stock exchanges, including: Frankfurt (LWB.F), München (LWB.MU), Hamburg (LWB.HM), SIX (Zürich) (LWB.SW), ASX (MSB.AX).

Mesoblast Ltd is an Australian biotechnology company specializing in the development of cellular and regenerative therapies. The company's business model focuses on utilizing its proprietary Mesenchymal Stem Cell technology platform to develop novel therapies for serious medical conditions. The company has three main divisions: Cardiovascular Diseases, Inflammatory Diseases, and Oncology, each responsible for the development of specific treatments. Mesoblast works closely with the academic community and the biopharmaceutical industry to validate its technology platform and bring its products to market. Mesoblast's product range includes Mesenchymal Stem Cell therapies for various indications. Currently, Mesoblast's product portfolio is still in clinical development, but the company has already achieved some important milestones. The Cardiovascular Diseases division is responsible for the development of mesenchymal stem cell therapies for the treatment of cardiovascular diseases. The company has already completed a Phase 3 clinical trial for its heart failure therapy, which has shown promising results. Additionally, Mesoblast's Chronic Heart Failure therapy is currently in clinical trials. The Inflammatory Diseases division includes anti-inflammatory stem cell therapies for the treatment of inflammatory diseases such as rheumatoid arthritis and graft-versus-host disease (GvHD). Mesoblast's GvHD therapy has already received approval from the US Food and Drug Administration and is currently available on the market. The Oncology division is responsible for the development of mesenchymal stem cell therapies for the treatment of cancer. Mesoblast's technology platform allows for targeting a wide range of cancer cells, and the company has already achieved positive results in a Phase 2 clinical trial with a cancer therapy. Another important area of business for Mesoblast is partnerships with other pharmaceutical and biotechnology companies. Mesoblast recently signed an agreement with Novartis to distribute its Hematopoietic Stem Cell Transplantation treatment in the EU region. Additionally, the company is working closely with Tasly Pharmaceuticals to develop a product upgrade for Tasly's prostate cancer medication. Mesoblast's cellular stem cell technology platform forms the foundation for its products and is a significant competitive advantage. Mesenchymal stem cells have the ability to differentiate into various types of cells such as bone, cartilage, adipose tissue, and muscle. Overall, Mesoblast is a company dedicated to the development of innovative cellular and regenerative therapies that have the potential to improve the lives of patients with serious diseases. The company has already achieved important milestones and is working towards bringing its therapies to market, enabling further growth for the company.

odotettu liikevaihto Mesoblast on 124,91 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Mesoblast on −52,76 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Mesoblast:n hinta-voitto-suhde (P/E) on tällä hetkellä −34,66. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Mesoblast-osakkeen arvostusta.

Mesoblast:n hinta-myynti-suhde (P/S) on tällä hetkellä 14,64. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Mesoblast-osakkeen arvostuskennuslukuna.

Mesoblast:n Eulpool-laatuscore on 3/10.

Mesoblast:n ISIN on AU000000MSB8. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Mesoblast:n WKN on A0DNPW. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Mesoblast:n ticker on MSB.AX. Tämä pörssinoteeraus käytetään Mesoblast-osakkeiden kauppaan pörssissä.

Mesoblast maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Mesoblast kuuluu sektoriin 'Terveydenhuolto'.

Mesoblast:n osingot jaetaan valuutassa USD.